Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Insider Selling

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down prior to trading on Thursday following insider selling activity. The stock had previously closed at $26.95, but opened at $25.16. Hims & Hers Health shares last traded at $26.27, with a volume of 6,054,360 shares traded.

Specifically, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $28.50, for a total value of $330,058.50. Following the sale, the chief financial officer now directly owns 118,960 shares of the company’s stock, valued at $3,390,360. This trade represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 3,236 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92. Following the completion of the transaction, the insider now owns 162,898 shares of the company’s stock, valued at $4,678,430.56. This represents a 1.95 % decrease in their position. The disclosure for this sale can be found here. In related news, insider Soleil Boughton sold 4,151 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $45.14, for a total transaction of $187,376.14. Following the completion of the transaction, the insider now owns 166,134 shares of the company’s stock, valued at $7,499,288.76. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Analyst Ratings Changes

A number of research firms have recently issued reports on HIMS. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Bank of America boosted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Leerink Partners lifted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Finally, Truist Financial decreased their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $38.25.

Hims & Hers Health Stock Performance

The firm has a market capitalization of $5.87 billion, a P/E ratio of 59.83 and a beta of 1.65. The stock has a 50-day moving average of $37.94 and a 200 day moving average of $30.50.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of the stock. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. UMB Bank n.a. raised its stake in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.